Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Diluted Average) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $72.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 15.42% to $72.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.9 million, a 15.42% increase, with the full-year FY2025 number at $72.9 million, up 15.42% from a year prior.
  • Shares Outstanding (Diluted Average) was $72.9 million for Q4 2025 at Phathom Pharmaceuticals, down from $73.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $73.4 million in Q3 2025 to a low of $38.0 million in Q1 2022.
  • A 4-year average of $54.9 million and a median of $54.8 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 11.35% in 2023, then surged 37.82% in 2024.
  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $39.1 million in 2022, then skyrocketed by 31.11% to $51.3 million in 2023, then increased by 23.18% to $63.2 million in 2024, then increased by 15.42% to $72.9 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Shares Outstanding (Diluted Average) are $72.9 million (Q4 2025), $73.4 million (Q3 2025), and $72.2 million (Q2 2025).